Emotion and treatment for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial studies if emotional health affects how well targeted therapy and immunotherapy work for people with advanced liver cancer. You will receive chemotherapy directly into the liver along with targeted drugs and immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have advanced liver cancer (BCLC stage B or C).
- You have not had any prior cancer treatment that affects the whole body.
- You have at least one tumor in the liver that can be measured on a scan.
- Your liver function is good (Child-Pugh score 7 or less).
- You are able to take pills by mouth and can perform daily activities with little or no help.
- You do not have a history of autoimmune diseases, severe mental health disorders, or other cancers in the last 3 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests a combination of liver-directed treatments and immunotherapy with a targeted drug for people whose liver cancer has spread to a few other organs. It aims to shrink tumors and improve outcomes.
This trial tests a personalized treatment plan for people whose advanced liver cancer (hepatocellular carcinoma) has progressed after initial targeted and immune therapy. It aims to find a next-step option tailored to your specific situation.
This trial tests two types of immunotherapy (atezolizumab with bevacizumab or durvalumab with tremelimumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. It aims to see if these treatments are safe and effective.
This trial tests whether adding a liver-directed treatment to standard systemic therapy can improve outcomes for people with liver cancer that cannot be removed. It may help shrink tumors or slow the disease while on current treatment.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.